Clinical trials
Completed Corneal Diseases trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
110 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 2 |
| 2005 | 4 |
| 2006 | 2 |
| 2007 | 6 |
| 2008 | 6 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 3 |
| 2012 | 6 |
| 2013 | 4 |
| 2014 | 6 |
| 2015 | 2 |
| 2016 | 7 |
| 2017 | 4 |
| 2018 | 5 |
| 2019 | 5 |
| 2020 | 7 |
| 2021 | 6 |
| 2022 | 5 |
| 2023 | 7 |
| 2024 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 110 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Eye Institute (NEI) | 8 |
| Kissei Pharmaceutical Co., Ltd. | 7 |
| Daniela Nosch | 4 |
| Benha University | 3 |
| Glaukos Corporation | 3 |
| Nidek Co. LTD. | 3 |
| Carl Zeiss Meditec, Inc. | 2 |
| Centre Hospitalier Universitaire de Saint Etienne | 2 |
| Federal University of São Paulo | 2 |
| Massachusetts General Hospital | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Corneal Diseases | 110 |
| Dry Eye Syndromes | 17 |
| Keratoconus | 12 |
| Eye Diseases | 11 |
| Conjunctival Diseases | 9 |
| Keratitis | 9 |
| Glaucoma | 8 |
| Cataract | 6 |
| Retinal Diseases | 6 |
| Corneal Ulcer | 5 |
Trials
Showing 26 to 50 of 110. Each trial links to its page on Pharma Observatory.
10 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.